Get the Stockscreener App
1.73
1.17%
0.02
After Hours:
1.70
-0.03
-1.73%
Essa Pharma Inc stock is traded at $1.73, with a volume of 150.15K.
It is up +1.17% in the last 24 hours and down -3.89% over the past month.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
See More
Previous Close:
$1.71
Open:
$1.72
24h Volume:
150.15K
Relative Volume:
0.16
Market Cap:
$76.79M
Revenue:
-
Net Income/Loss:
$-28.54M
P/E Ratio:
-2.7031
EPS:
-0.64
Net Cash Flow:
$-22.72M
1W Performance:
-0.57%
1M Performance:
-3.89%
6M Performance:
-65.74%
1Y Performance:
-79.65%
1-Day Range:
$1.70
$1.7677
1-Week Range:
$1.70
$1.81
52-Week Range:
$1.40
$11.67
Essa Pharma Inc Stock (EPIX) Company Profile
Name
Essa Pharma Inc
Sector
Industry
Phone
(778) 331-0962
Address
SUITE 720, VANCOUVER, BC
Compare EPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPIX
Essa Pharma Inc
|
1.73 | 76.79M | 0 | -28.54M | -22.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Essa Pharma Inc Stock (EPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-04-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-04-21 | Initiated | Piper Sandler | Overweight |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-25-19 | Initiated | Oppenheimer | Outperform |
View All
Essa Pharma Inc Stock (EPIX) Latest News
Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
EPIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Shareholders of ESSA Pharma Inc. Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your RightsEPIX - PR Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
EPIX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit - PR Newswire
ESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
EPIX Investor Notice: Shareholder Rights Law Firm Robbins - GlobeNewswire
EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Malaysian Reserve
Stockholder Alert: Robbins LLP Informs Investors of the ESS Pharma Inc. Class Action - cnhinews.com
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
EPIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
ESSA Pharma Misled Investors Over Cancer Treatment, Lawsuit Says - Bloomberg Law
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against ESSA Pharma Inc. (EPIX) - EIN News
Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
Short Interest in ESSA Pharma Inc. (NASDAQ:EPIX) Declines By 5.3% - MarketBeat
ESSA Pharma (NASDAQ:EPIX) Share Price Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
3 Promising US Penny Stocks With Market Caps Under $80M - Simply Wall St
ESSA Pharma Inc. (NASDAQ:EPIX) Sees Significant Growth in Short Interest - MarketBeat
ESSA Pharma (NASDAQ:EPIX) Stock Price Passes Below 50 Day Moving Average – What’s Next? - Defense World
ESSA Pharma (NASDAQ:EPIX) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Surprising News! ESSA Pharma’s Big Breakthrough Expected Soon. - Jomfruland.net
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit? - Yahoo Finance
ESSA Pharma’s Cash Management: A Potential Risk to Shareholder Value and Market Stability - TipRanks
ESSA Pharma Inc. Reports Strategic Shift Amid Losses - TipRanks
ESSA Pharma: Fiscal Q4 Earnings Snapshot - The Ridgefield Press
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 - Barchart
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2024 - Marketscreener.com
ESSA Pharma (NASDAQ:EPIX) Issues Earnings Results - MarketBeat
SEC Form 10-K filed by ESSA Pharma Inc. - Quantisnow
ESSA Pharma Halts Key Cancer Drug Trials, Initiates Strategic Review Amid Clinical Setback - StockTitan
ESSA Pharma ends long-standing license agreement with cancer agencies - Investing.com
ESSA Pharma Inc. Adopts Executive Severance Plan**United States Securities and Exchange Commission Filing – ESSA Pharma Inc. submitted a current report on Form 8-K, dated June 5, 2024, announcing the adoption of the ESSA Pharma Inc. Severance P - Defense World
ESSA Pharma Introduces New Executive Severance Plan - TipRanks
RTW Investments LP Grows Stake in ESSA Pharma Inc. (NASDAQ:EPIX) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc.EPIX - PR Newswire
Applied Digital, ESSA Pharma And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session - MSN
Piper Sandler Downgrades ESSA Pharma (EPIX) - MSN
United States shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
Thinking about buying stock in Adverum Biotechnologies, Roma Gre - GuruFocus.com
Oppenheimer Downgrades ESSA Pharma (EPIX) - MSN
Essa Pharma Inc Stock (EPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):